LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)

BACKGROUND: SARS-CoV-2 vaccine efficacy (VE) against asymptomatic infection and impact on viral shedding during breakthrough infections have critical implications for pandemic control. AZD1222 (ChAdOx1 nCoV-19; 2 doses, 4 weeks apart) demonstrated VE of 74.0% (95% CI 65.3, 80.5) against the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobieszczyk, Magdalena, Falsey, Ann R, Robb, Merlin L, Tieu, Hong-Van, McElrath, Julie, Corey, Lawrence, Neuzil, Kathleen, Tong, Tina, Isaacs, Margaret Brewinski, Maaske, Jill, Jepson, Brett, Sproule, Stephanie, Kelly, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644203/
http://dx.doi.org/10.1093/ofid/ofab466.1637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644203/
http://dx.doi.org/10.1093/ofid/ofab466.1637

Ejemplares similares